2021 ASH Annual Meeting: CAR T-Cell Therapy | Supplements And Featured Publications

The 2021 ASH Annual Meeting: CAR T-Cell Therapy priority report is a digital version of the print publication spanning some of the groundbreaking abstracts in CAR T-cell therapy that were presented during the conference.

Tisagenlecleucel Displays Promising Efficacy Results Across Subgroups in R/R FL

December 11, 2021

Tisagenlecleucel produced a high overall response rate and complete response rate in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial.

Axi-Cel Demonstrates Ongoing Survival Benefit in Relapsed/Refractory iNHL

December 11, 2021

Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.

Liso-cel Bests Standard of Care in Second-Line Treatment of LBCL

December 11, 2021

Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.